-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Aerovate Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2020 to Q2 2024.
- Aerovate Therapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$26.2M, a 28.7% decline year-over-year.
- Aerovate Therapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$94.2M, a 38.6% decline year-over-year.
- Aerovate Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$81.4M, a 52.9% decline from 2022.
- Aerovate Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$53.2M, a 131% decline from 2021.
- Aerovate Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$23M, a 159% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)